Researchers create a nanobioconjugate drug that specifically targets glioblastoma multiforme by blocking the production of laminin-411, promoting tumor cell death. Human clinical trials are anticipated to begin soon, offering new hope for brain cancer treatment.
In a phase II study, patients with locally advanced and metastatic NSCLC experienced significant increases in survival time when treated with TTF therapy in combination with chemotherapy. The therapy has also been shown to have clinical efficacy in human trials for other solid tumors, including recurrent glioblastoma.
A vaccine that targets a genetic mutation driving aggressive glioblastoma improved patient survival, with median overall survival of 26 months compared to 15 months for control group. Limited side effects were reported.
A new vaccine has been shown to extend survival for patients with glioblastoma, the most deadly form of brain cancer, by eliminating aggressive cancer cells carrying the EGFRvIII marker. The study found that adding the vaccine to standard therapy improved median survival time from 15 months to 26 months.
Researchers at Washington University School of Medicine discovered a new drug target that can improve the effectiveness of radiation therapy for hard-to-treat cancers. The enzyme cytosolic phospholipase A2 (cPLA2) promotes tumor angiogenesis, enabling tumors to overcome radiation effects.
A novel combination therapy of temozolomide and a Notch inhibitor has been shown to be highly effective in reducing tumor growth and recurrence in glioblastoma multiforme. This approach aims to target cancer stem cells, which are resistant to traditional therapies.
Researchers at Georgia Institute of Technology develop a system to excavate brain tumor cells by directing them away from their location in the brain to a gel-based 'sink' where they can be removed or killed. The goal is to improve survival rates and reduce toxic effects of treatment for pediatric medulloblastomas.
Researchers have demonstrated the use of iron oxide nanoparticles to deliver antibodies to implanted brain tumors, enhancing tumor visibility via MRI while killing cancer cells. The particles also show potential for targeted therapy against glioblastoma multiforme, a common and aggressive primary brain tumor.
Researchers at UCLA have developed a microfluidic image cytometry platform that can measure cell-signaling pathways in brain tumor samples at the single-cell level. This technology marks an advance toward predictive and personalized medicine, enabling physicians to predict patient prognosis and guide treatment.
A study at the American Association of Physicists in Medicine meeting found that intensity modulated arc therapy can effectively treat brain tumors while reducing damage to surrounding sensitive tissues, such as ears and parts of the brain. This technique uses continuous rotation of X-ray sources around a patient during treatment.
The current standard of care for brain cancer triggers biological responses that may feed the disease, according to Boston College researchers. This can lead to an escalation of conditions favorable to tumor cell survival and growth.
A new study found that an enriched environment can reduce cancer growth in mice by activating a nervous system pathway that decreases leptin levels, a hormone linked to appetite and cancer growth. The effect was observed in models of melanoma and colon cancer, with tumors reduced by up to 80% after three weeks of enrichment.
Researchers identify a protein released by neural stem cells that induces signaling in glioblastoma cells, causing them to differentiate. This discovery could lead to new therapy concepts targeting tumor stem cells and potentially destroying the aggressive brain tumors.
A new experimental drug targeting the Hedgehog pathway has shown early signs of efficacy in pediatric brain tumor patients, with some still on treatment a year after diagnosis. The study's findings have given the green light for larger Phase II studies to advance targeted therapies against medulloblastomas.
A modified measles virus has been shown to effectively kill medulloblastoma cells in laboratory studies and mouse models, suggesting its potential as a new treatment option for childhood brain tumors. The vaccine strain targets the CD46 receptor, which is highly expressed in multiple tumor types.
A Northwestern University study found that brain cancer patients with malignant gliomas tend to overestimate their quality of life compared to their caregivers. The research suggests that caregivers play a crucial role in providing a more accurate assessment of the patient's well-being.
A new study identifies a crucial gene in pediatric high-grade glioma, which may lead to the development of more effective drugs. The research found that the PDGFRA gene is unusually active in childhood cancer and is likely to be an important drug target.
Researchers at Thomas Jefferson University found that hypofractionated stereotactic radiotherapy significantly improves survival rates for patients with recurrent brain cancers, while minimizing side effects. The treatment provides longer survival without experiencing common chemotherapy and targeted therapy side effects.
A study led by St. Jude Children's Research Hospital identified a cancer gene unusually active in some childhood brain tumors, providing a new treatment target for high-grade gliomas (HGGs). The research found significant differences between genetic defects in children and adults with HGG.
Researchers found that PDE5 inhibitors increase blood-brain barrier permeability to Herceptin, boosting effectiveness against lung and breast cancer brain metastases. The combination of vardenafil plus Herceptin improved survival by 20% in mouse models.
Researchers have found that parvoviruses can completely regress malignant brain tumors in rats and human gliomas. The viruses target cancer cells without affecting healthy tissue, making them a potential new approach to treating glioblastoma.
Researchers at Ohio State University have developed nanoparticles that can enhance MRI scans and surgical procedures for brain tumor removal. The magnetic and fluorescent nanocomposites can help doctors visualize tumors before surgery, allowing for more precise removal.
A new study links brain tumor growth to reduced expression of over 600 immune system genes, revealing the complexity of the immune response to cancer. The research found that immune function genes were suppressed in almost 70% of genes examined, contradicting previous assumptions.
A study by researchers at the University of Texas M.D. Anderson Cancer Center has identified a potential new therapy for brain tumors by analyzing DNA methylation patterns. The discovery may help identify patients with more favorable outcomes and offer a targeted treatment approach.
Scientists have discovered that residual glioblastoma cells have different properties than those found in the tumor mass, making them more mobile and resistant to treatment. This breakthrough could lead to new therapeutic approaches against this aggressive brain cancer.
Researchers discovered new pyrimidine compounds that target Src tyrosine kinases in medulloblastoma cells, showing reduced cell proliferation and tumor progression. These compounds may offer a more effective treatment option for childhood brain cancer, with potential synergistic effects when combined with chemotherapy.
Researchers have developed a minimally invasive endoscopic procedure that can safely remove large brain tumors from an area at the bottom of the skull, near the sinus cavities. The study found that this approach resulted in complete tumor removal in 96% of patients and could be a game-changer for patients with pituitary macroadenomas.
Research at Johns Hopkins Medicine found that underprivileged African-American, Hispanic, and low-income patients with brain tumors are significantly less likely to be referred to high-volume specialty hospitals. This finding contradicts federal health care agency recommendations for equal access and quality of care.
Glioblastoma cells use miR-451 to sense glucose availability, slowing cell proliferation and increasing migration. High miR-451 levels correlate with shorter survival, suggesting the molecule as a biomarker for predicting patient prognosis.
Recent clinical and scientific advancements in nervous system cancers have improved our understanding of molecular changes and new therapies for patients. The March issue of Archives of Neurology features articles on various topics, including increased melanoma risk among Parkinson's disease patients and new insights into glioma risk.
Researchers at Stanford University School of Medicine have found that disrupting the SDF-1/CXCR4 interaction can prevent the recruitment of vasculogenic cells to the tumor site, blocking postirradiation development of functional tumor vasculature and tumor regrowth. This approach may be applicable to treating glioblastoma multiforme.
Researchers at Stanford University have discovered a way to prevent glioblastoma cells from growing back after radiation by blocking their access to oxygen and nutrients. The discovery, using the small molecule AMD3100, has shown promise in preventing tumor recurrence.
Researchers at Stanford University School of Medicine found that blocking blood vessel formation prevents brain tumor recurrence in mice. Disrupting the SDF-1/CXCR4 interaction prevented tumor regrowth by abrogating functional tumor vasculature.
Researchers have identified a potential therapeutic target for brain cancer, the A20 protein, which is highly expressed in glioblastoma stem cells. Decreasing levels of A20 in these cells reduces their growth and induces cell death, increasing survival rates in animal models.
A key mechanism that makes certain brain cells become tumorous has been identified by researchers. The tumours occur most often spontaneously but can also be part of inherited disease Neurofibromatosis type 2.
Research finds that selective brain damage, particularly in parietal regions, can modulate human spirituality and religious attitudes. The study identified a causative link between specific brain lesions and changes in self-transcendence, a personality trait reflecting spiritual feeling and behavior.
A phase 2 trial of denosumab has shown encouraging results in treating a rare type of brain tumor. The study found that 86% of patients experienced a tumor response, including some with lung lesions, and reported clinical benefits such as reduced pain and improved mobility.
Alexander Ksendzovsky, a third-year medical student, has been awarded the Lucien Rubenstein Award for his groundbreaking research on a potential vaccine to fight malignant brain tumors. The American Brain Tumor Association recognized his outstanding work as part of their annual Research Award Program.
Researchers discovered that gliomas can evade EGFR inhibitors by expressing alternative genes like KLHDC8, which halts tumor growth. This finding provides potential new targets and treatment strategies for brain tumors.
Researchers have identified two genes, C/EPB and Stat3, which are responsible for the most aggressive forms of human brain cancer. These genes work together to transform normal brain cells into highly aggressive cells, making them a major target for new treatments.
Researchers at the University of Central Florida have found a protein, TRPC6, that could hold the key to treating GBM, a type of malignant brain tumor. Knocking down this protein's expression can stop tumor growth and spread.
The new guidelines offer a range of therapeutic options and provide evidence-based recommendations for treating brain metastases. The guidelines aim to improve patient outcomes by identifying best treatment practices and fostering support for ongoing research.
Researchers identify specific DNA segment C19MC containing miRNA genes associated with aggressive CNS-PNET tumors. High expression of these miRNAs stimulates growth and prevents normal neural stem cell development.
Atoh1, a transcription factor critical for fetal development, is necessary for the development of many forms of medulloblastoma. Shutting down Atoh1 in susceptible brain cells prevented medulloblastoma from developing in mice, suggesting it as a potential target for new drug treatments.
A recent study published in the Journal of the National Cancer Institute found no significant link between increased cell phone usage and brain tumor incidence. The research analyzed data from Denmark, Finland, Norway, and Sweden over a 30-year period, concluding that induction periods may be longer than previously thought.
Researchers found that the master gene Math1 is critical to the development of medulloblastoma, a deadly disease that affects children and young adults. Removing or inactivating Math1 may work as a treatment, but its effectiveness depends on the stage of brain development.
Duke University researchers have found a way to increase the effectiveness of radiation therapy against glioma brain tumors by blocking a specific signaling pathway in cancer stem cells. This breakthrough could lead to more effective treatment options for patients with glioblastoma and other brain cancers.
Researchers at Ohio State University have developed a tumor-attacking virus that kills brain-tumor cells and blocks the growth of new tumor blood vessels. The virus, called RAMBO, was tested in animal models and showed promise in treating aggressive brain cancer with a survival rate of 54 days.
A new miniature microscope enables neurosurgeons to visualize brain tumors in real-time, allowing for more precise removal and accurate diagnosis. This technology has the potential to reduce surgery time by up to 40 minutes and improve patient outcomes.
Researchers found that multiple sessions of stereotactic radiosurgery (SRS) result in less brain swelling compared to a single high-dose treatment. This innovative approach offers good tumor control with fewer side effects and less time than conventional therapy.
Long-term brain tumor survivors in childhood experience ongoing cognitive problems, with lower levels of education, employment, and income compared to siblings and other cancer survivors. Medical complications such as radiation and surgery also play a significant role in these impairments.
Researchers at University Hospitals Case Medical Center report promising results from a study treating glioblastoma multiforme with Gamma Knife radiosurgery, increasing patient survival rates by almost four months compared to traditional radiotherapy alone.
Two UCSF teams, one for diabetes and one for brain tumors, have received grants from the California Institute for Regenerative Medicine to advance stem cell-based therapies. The goal is to file new drug applications with the FDA within four years, driving potential therapies toward clinical trials.
The first national and evidence-based guidelines for brain metastases have been released in the US, providing a framework for treating patients with brain tumors. The guidelines cover various therapeutic options, evidence-based decision-making, and demographic factors that influence clinical decisions.
ANG1005 demonstrates disease control in over 70% of patients with progressive gliomas and brain metastases, with significant reductions in tumor size observed. The drug successfully crosses the blood-brain barrier without CNS toxicity or immunogenicity.
The Translational Genomics Research Institute has been awarded $691,930 to develop brain tumor research using in silico simulations. The project will utilize comprehensive genomic data involving 40 brain tumor models and 20 proven types of targeted therapies.
Researchers have found that a standard treatment protocol can improve survival rates nearly two-fold for pediatric patients with choroid plexus tumors. The study suggests that chemotherapy and radiation can be effective in reducing mortality rates, contradicting previous research on surgical resection.
A Johns Hopkins study found that Hispanic children diagnosed with brain tumors receive specialized care at one-third the rate of other children, despite efforts to equalize access. The research highlights persistent gaps in care among certain patients and raises concerns about the future impact on this growing demographic.
Fernandez-Valle's research aims to identify proteins that could deliver cancer-fighting drugs to NF2 tumors, potentially improving lifestyles and extending patients' lives. She has established nationally affiliated clinics in Florida, bringing together physicians with expertise in treating the disease.
Patients with brain tumors treated with WBRT plus SRS experience significant decline in learning and memory function compared to those receiving SRS alone. The study concludes that SRS alone combined with close clinical monitoring is the preferred treatment strategy for patients newly diagnosed with one to three brain metastases.